Diego Miralles Gines, President and Head of R&D at Artiva Biotherapeutics, Inc., filed a Form 4 on September 11, 2026, reporting the acquisition of restricted stock units and a stock option grant dated September 9, 2026.

Key Highlights

  • RSU Award: 45,000 restricted stock units were acquired on September 9, 2026, at a price of $0, under the issuer's 2024 Equity Incentive Plan.
  • Stock Option Grant: An employee stock option (right to buy) covering 135,000 shares of common stock was granted on September 9, 2026, at an exercise price of $10.79.
  • Option Vesting: Beginning September 8, 2026, 1/48th of the option shares vest in equal monthly installments over a four-year period.
  • Option Expiration: The stock option expires on September 8, 2036.
  • Resulting Ownership: Following the transactions, the reporting person directly holds 122,500 shares of common stock and 135,000 derivative securities.
  • Filing Basis: Both transactions are coded as acquisitions (Code A) and reported as direct ownership.

Equity Grants to Artiva Biotherapeutics' President and Head of R&D

According to the filing, Diego Miralles Gines, serving as President and Head of R&D at Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), received two equity awards on September 9, 2026. The first was a restricted stock unit award of 45,000 shares of common stock granted at $0, issued under the company's 2024 Equity Incentive Plan. Following this transaction, the reporting person's direct beneficial ownership of common stock stands at 122,500 shares, the filing states.

The second award reported is an employee stock option granting the right to buy 135,000 shares of common stock at an exercise price of $10.79 per share. The filing discloses that the option vesting begins September 8, 2026, with 1/48th of the shares subject to the option vesting in equal monthly installments over a four-year period. The option is set to expire on September 8, 2036. The price of the derivative security at grant is listed as $0, and the resulting direct beneficial ownership of derivative securities is reported as 135,000.

The Form 4 was signed by Jennifer Bush as attorney-in-fact on September 11, 2026, and filed the same day. Both transactions are reported as direct ownership with no indirect beneficial ownership disclosed in connection with these awards.

What Was Disclosed

The filing reports two equity awards to Artiva Biotherapeutics' President and Head of R&D: a 45,000-share RSU grant at $0 under the 2024 Equity Incentive Plan, and a 135,000-share stock option at $10.79 per share vesting monthly over four years beginning September 8, 2026.